

Joel D Levenson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4380317/publications.pdf>

Version: 2024-02-01

28
papers

3,781
citations

394421

19
h-index

501196

28
g-index

30
all docs

30
docs citations

30
times ranked

6553
citing authors

#	ARTICLE	IF	CITATIONS
1	Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 869-872.	7.2	10
2	Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 68-79.	9.4	65
3	Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1108-1115.	2.8	2
4	mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation. <i>Haematologica</i> , 2021, 106, 3008-3013.	3.5	6
5	A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. <i>Leukemia</i> , 2020, 34, 1646-1657.	7.2	54
6	Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 132.	5.0	19
7	5-Azacytidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. <i>Clinical Cancer Research</i> , 2020, 26, 3371-3383.	7.0	98
8	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 642-655.	4.1	39
9	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019, 33, 1291-1296.	7.2	36
10	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1115-1126.	4.1	20
11	Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy. <i>Nature Communications</i> , 2019, 10, 620.	12.8	60
12	Coamplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	7.1	23
13	Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?. <i>Frontiers in Oncology</i> , 2018, 8, 458.	2.8	30
14	Statins enhance efficacy of venetoclax in blood cancers. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	61
15	The BCL-2-Selective Inhibitor Venetoclax Spares Activated T-Cells during Anti-Tumor Immunity. <i>Blood</i> , 2018, 132, 3704-3704.	1.4	8
16	Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models. <i>Blood</i> , 2018, 132, 562-562.	1.4	22
17	5-Azacytidine Induces NOXA and PUMA Expression to Prime AML Cells for Venetoclax-Mediated Apoptosis. <i>Blood</i> , 2018, 132, 2644-2644.	1.4	1
18	Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 1376-1393.	9.4	105

#	ARTICLE	IF	CITATIONS
19	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. <i>Nature Communications</i> , 2017, 8, 365.	12.8	44
20	A New Staple: Peptide-Targeted Covalent Inhibitors. <i>Cell Chemical Biology</i> , 2016, 23, 1043-1044.	5.2	0
21	Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra117.	12.4	130
22	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1132-1144.	4.1	231
23	Chemical parsing: Dissecting cell dependencies with a toolkit of selective BCL-2 family inhibitors. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1050155.	0.7	10
24	MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1837-1847.	4.1	102
25	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	6.4	118
26	Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. <i>Cancer Cell International</i> , 2015, 15, 5.	4.1	12
27	Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer. <i>Molecular Cancer</i> , 2015, 14, 126.	19.2	42
28	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013, 19, 202-208.	30.7	2,426